Post Marketing Surveillance Study for ONIVYDE in South Korea.
Latest Information Update: 29 Sep 2021
At a glance
- Drugs Irinotecan (Primary) ; Fluorouracil; Folinic acid
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Shire; Takeda
- 27 Sep 2021 Status changed from recruiting to completed.
- 14 Mar 2018 Status changed from not yet recruiting to recruiting.
- 28 Feb 2018 New trial record